Title for MeetingAbstracts
Alphabetical listing of titles
HCV and immune response.
HCV E2 Genetic Variability in HCV-HIV-Coinfected Patients Treated with Interferon-Ribavirin.
HCV GENETIC DIVERSITY AND RESISTANCE: IMPLICATIONS FOR DRUG DISCOVERY AND DEVELOPMENT.
HCV genotype analysis in HIV co-infected patients treated with alpha-interferon.
HCV Genotypic Analysis of Amplicons from a Transcription Mediated Amplification Assay Using an HCV 5'NC Genotyping Kit.
HCV impact on depressive symptoms in HIV-infected adults with alcohol problems.
HCV increases neurocognitive risk in HIV+ substance abusers.
HCV infection influences lipid abnormalities in HIV/HCV co-infected patients ungergoing HAART.
HCV infection is associated with lower levels of serum LDL cholesterol and total cholesterol in HIV-positive individuals.
HCV markers testing like as HIV risk monitoring tool in penitentiaries.
HCV Population Study in the U.S.: an Incentive for Further Clinical Trials.
HCV Replicon Cells Treated with the Protease Inhibitor, SCH6, Show Dramatic Disappearance of HCV Protein and RNA.
HCV REPLICONS: POTENTIAL APPLICATIONS FOR DRUG SCREENING AND DRUG RESISTANCE.
HCV Resistance to Peg-Interferon/Ribavirin Therapy Is Associated with Increased Immune Activation in HIV/HCV Co-infected Patients.
HCV RNA Assays: Brand Name or Generic?
HCV RNA in hemophiliacs with antibody to hepatitis C virus (HCV): relationship to HIV infection and liver failure.
HCV RNA Kinetic Response to PEG-Interferon and Ribavirin in HIV Co-Infected Patients.
HCV RNA significance in mother-to-infant transmission of hepatitis C.
HCV seropositivity in children born to HIV seropositive mothers.
HCV Transmission and the Sharing of Cookers, Cotton Filters, and Rinse Water.
HCV viral load in HCV-HIV-coinfected patients treated with protease inhibitors.
HCV viremia in HIV-positive patients negative for HBs Ag.
HCV virus infection in HIV (+) and HIV (-) hemophilic children in BS.AS.- Argentina.
HCV-antibody testing: challenging the Boehringer Mannheim modular test concept.
HCV-related factors but not HIV-related factors at baseline predict the response to treatment with peginterferon alfa-2a (40KD) (Pegasys) plus ribavirin (Copegus) in patients with HCV/HIV co-infection: Predictor analysis from the APRICOT study.
HCV/HIV co-infection and vertical transmission in the European paediatric HCV network.
HCV/HIV prevalence in women attending the Ante Natal Clinic of Lacor Hospital in northern Uganda.
HDC/ABMT: Implications for Policy, Delivery and Practice.
HDL-cholesterol and apolipoprotein A1 as simple predictors of outcome in HIV-positive patients.
Head and gaze stability during locomotion: I. Analysis of linear head movement.